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OBJECTIVE—IKZF1 encoding Ikaros, an essential regulator of
lymphopoiesis and immune homeostasis, has been implicated in
the development of childhood acute lymphoblastic leukemia
(C-ALL). Because recent genome-wide association (GWA) studies
have linked a region of the 39-UTR of IKZF1 with C-ALL suscep-
tibility, we tested whether IKZF1 is associated with the autoim-
mune disease type 1 diabetes.
RESEARCH DESIGN AND METHODS—rs10272724 (T.C)
near IKZF1 at 7p12 was genotyped in 8,333 individuals with type
1 diabetes, 9,947 control subjects, and 3,997 families of European
ancestry. Association was tested using logistic regression in the
case-control data and by the transmission disequilibrium test in
the families. Expression data for IKZF1 by rs10272724 genotype
were obtained using quantitative PCR of mRNA/cDNA generated
from peripheral blood mononuclear cells from 88 individuals,
whereas expression data for ﬁve other neighboring genes were
obtained from the online Genevar dataset.
RESULTS—The minor allele of rs10272724 (C) was found to be
protective from type 1 diabetes (odds ratio 0.87 [95% CI 0.83–0.91];
P =1 . 13 10
211). rs10272724 was not correlated with levels of two
transcripts of IKZF1 in peripheral blood mononuclear cells.
CONCLUSIONS—The major susceptibility genotype for C-ALL
confers protection from type 1 diabetes. Our ﬁnding strengthens
the link between autoimmunity and lymphoid cancers. Further
investigation is warranted for the genetic effect marked by
rs10272724, its impact on IKZF1, and the role of Ikaros and other
family members, Ailios (IKZF3) and Eos (IKZF4), in autoimmu-
nity. Diabetes 60:1041–1044, 2011
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KZF1 encodes Ikaros, a zinc-ﬁnger transcription
factor with a regulatory role in lymphopoiesis and
the maintenance of cytokine expression in mature
lymphocytes (1,2). Mice with a null mutation in
IKZF1 (Ikaros
2/2) display complete penetrance of leuke-
mia, increased CD4
+ to CD8
+ T-cell ratios, and defects in
T-cell maturation, including decreased T-cell receptor
signaling thresholds during central tolerance (1). Mice
heterozygous for the null mutation in IKZF1 (Ikaros
+/2)
exhibit milder features, but abnormalities including re-
duced B-cell precursors, a highly increased proliferative
response to T-cell receptor engagement, and high rates of
T-cell leukemia and lymphomas have been observed (3).
Human studies suggest a speciﬁc role for Ikaros in
childhood acute lymphoblastic leukemia (C-ALL). Devel-
opment of C-ALL is linked to somatically acquired mutations
that add to inherited cancer susceptibility alleles (4). In 2009,
deletions of IKZF1 were reported in 28.6% of C-ALL affected
adults (5) and in 83.7% of BCR-ABL1 C-ALL patients exam-
ined (6). Combined, the human and murine studies suggest
that diminished expression of IKZF1 interrupts lymphocyte
development, creating conditions that maintain the rapidly
dividing lymphoblasts that characterize ALL.
Two recent genome-wide association (GWA) studies
have identiﬁed a C-ALL susceptibility locus near IKZF1
(7,8). The identiﬁed C-ALL-associated single nucleotide
polymorphisms (SNPs), rs4132601 (T.G) and rs11978267
(A.G), as well as two others near IKZF1, rs11980379 (T.
C) and rs10272724 (T.C), showed evidence of association
with type 1 diabetes in a separate GWA study (P = 2.0 3
10
26, 2.6 3 10
26, 2.5 3 10
26, and 1.4 3 10
26, respectively;
www.t1dbase.org), although not at the level the authors
required for follow-up (P , 1 3 10
26) (4). All four SNPs
are in high linkage disequilibrium (LD, r
2.0.98) in the
British 1958 Birth Cohort (B1958) controls (http://www.
b58cgene.sgul.ac.uk), suggesting they mark the same po-
tential causal variant for type 1 diabetes. Type 1 diabetes is
a disease of abnormal immunity, wherein autoimmune
destruction of pancreatic b-cells results in a state of insulin
dependency (8,9). Type 1 diabetes results from the in-
ﬂuence of environmental factors acting on an underlying
genetic susceptibility (9). Although no direct link between
IKZF1 and type 1 diabetes has been reported, the pre-
viously reported, but not highlighted or followed up, as-
sociation of the chromosome 7p12.2 region containing
IKZF1 with type 1 diabetes (10; www.t1dbase.org), the
immunologic importance of IKZF1 (11), and the associa-
tion of IKZF1 with susceptibility to C-ALL (7,8) prompted
us to select the SNP most associated with type 1 diabetes,
rs1027274 (T.C) (P = 1.4 3 10
26) near IKZF1, for follow-
up genotyping to assess association with type 1 diabetes
and to determine whether a common genetic component
exists for C-ALL and type 1 diabetes.
RESEARCH DESIGN AND METHODS
Samples. A total of 8,333 type 1 diabetes cases, 9,947 controls, and 3,997
families were genotyped at rs10272724using TaqMan(Supplementary Methods).
All samples were of white European ancestry. Cases were diagnosed with type 1
diabetes before 17 years of age (mean age at diagnosis = 7.8 years) and were
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BRIEF REPORTfrom the Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes
and Inﬂammation Laboratory Genetic Resource Investigating Diabetes study
(http://www.childhood-diabetes.org.uk/grid.shtml). Controls were obtained from
the British 1958 Birth Cohort (n = 6,899; http://www.cls.ioe.ac.uk/studies.asp?
section=000100020003) and the WTCCC UK Blood Service (UKBS) sample col-
lection (n = 3,048) (10,12).
Statistical analysis. STATA version 10 (StataCorp LP, College Station, TX)
was used to perform association analyses (http://www.stata.com). rs10272724
was in Hardy-Weinberg equilibrium in unaffected parents and control subjects
(P . 0.05). Case-control data were modeled using logistic regression, with
disease status as the outcome variable and counts of the minor allele (coded 0,
1, and 2) as the independent variable, assuming a multiplicative allelic effects
model. Geographic region was included as a covariate in the model (Sup-
plementary Methods). Families were analyzed using the transmission dis-
equilibrium test (13) (Supplementary Methods). The interdependency of
rs10272724 and rs4948088 in the 7p12 region was examined by stepwise
logistic regression.
Peripheral blood mononuclear cell isolation and preparation of DNA
and RNA. Peripheral blood mononuclear cells (PBMCs) were puriﬁed from
heparinized blood diluted 1:1 in PBS (without Ca
2+ and Mg
2+, GIBCO, Invi-
trogen, Carlsbad, CA), and 15 mL aliquots were layered onto 10 mL aliquots of
Lympholyte (Cedarlane Laboratories Ltd., Burlington, Ontario) followed by
centrifugation at 800g for 20 min at room temperature. The harvested PBMC
layer was washed twice with ice-cold PBS and centrifuged at 300g for 10 min
at 4°C. Pellets were resuspended in TRIzol (Invitrogen) and stored at 280°C in
aliquots of 10 3 10
7 cells/mL. Total RNA from 1 3 10
7 PBMCs in TRIzol was
prepared using chloroform extraction followed by puriﬁcation with the
RNeasy Mini kit (QIAGEN, Hilden, Germany), according to the manufacturer’s
instructions. RNA quality was assessed using an Agilent 2100 Bioanalyser, and
concentration was evaluated by Nanodrop (Thermo Scientiﬁc, Waltham, MA).
First strand DNA synthesis was carried out on 1 mg of RNA using Superscript
III RT kit and oligo-dT (Invitrogen).
Quantitative PCR evaluation of IKZF1 expression. Quantitative (q)PCR
primers and probe were designed to two transcripts of IKZF1, herein referred
to as “Isoform 1” and “Isoform 2” (Supplementary Methods). Probes were la-
beled with the ﬂuorochrome FAM and quenched using TAMRA. qPCR assays
contained 5 mL of 1:10 dilution of oligo-dT primed cDNA, prepared as de-
scribed above, in 20 mL assays. Cycle threshold (Ct) values were measured
using a 7900HT ABI prism (Applied Biosystems, Carlsbad, CA) and analyzed
using SDS v2.1 software (ABI). qPCR reactions were run in triplicate, and the
DCt for the transcript level qPCRs was calculated using the IKZF1 Isoform 1
or Isoform 2 qPCR Ct value minus the single copy gene b2 microglobulin qPCR
Ct value. Expression values were compared via one-way ANOVA using Prism
software (GraphPad Software Inc., La Jolla, CA).
mRNA expression of genes near rs10272724. Correlation between
rs10272724 and expression in three types of cell lines (primary ﬁbroblasts, Epstein–
Barr virus-immortalized lymphoblastoid cell lines, and phytohemagglutinin-
stimulated primary T-cells) derived from umbilical cord samples of 75 newborns
of Western European origin via the GenCord project was examined in silico
(14) using the publicly available HapMap online GENe Expression VARiation
(Genevar) resource (http://www.sanger.ac.uk/resources/software/genevar/).
Nine probes that passed quality control assessment (Supplementary Table 1)
were evaluated for correlation of mRNA expression with rs10272724 genotype
by linear regression using the Genevar 2.0.1 Java tool (15) (Supplementary
Methods). A P , 0.0056 signiﬁcance threshold was used within each cell type
based on a Bonferroni correction for testing nine transcripts.
Donors. Blood for qPCR experiments was collected from 88 nondiabetic
donors (rs10272724: 44 TT, 33 CT, 11 CC) selected from a pregenotyped bio-
resource and processed within 4 hours (www.cambroidgebioresource.org.uk).
Study ethics. All DNA samples were collected with ethical approval from the
National Health Service Cambridgeshire Research Ethics Committee. Written
consent was obtained from all individuals.
RESULTS
The minor allele of rs10272724 (T.C) near IKZF1 was
protective from type 1 diabetes (odds ratio [OR] 0.87 [95%
CI 0.83–0.91], P =4 . 83 10
29; Table 1, Supplementary Table
2). No evidence of association of rs10272724 with sex or
age-at-diagnosis was obtained (P . 0.1). Some samples
overlapped with those used in the previous GWA study for
type 1 diabetes (10). However, in each of the sample sets
used by Barrett et al. (10) and in our unique samples, the
effect is in the same direction and the overall signiﬁcance is
increased, suggesting the effect is not solely attributable to
the original samples (Table 1). The minor allele of
rs10272724 was also protective in the families with type 1
diabetes, i.e., under-transmitted to affected offspring (Table 1;
relative risk 0.87 [95% CI 0.81–0.93], P =7 . 63 10
25).
Combined, these results indicate that the minor allele, C, of
rs10272724 at 7p12.2 is convincingly associated with a re-
duced risk of type 1 diabetes (P =1 . 13 10
211). Barrett et al.
(10) reported a replicated association with rs4948088 (C.A)
with type 1 diabetes in the 7p12.1 region, 554 kb downstream
of IKZF1. However, this SNP, marking a conﬁrmed type 1
diabetes locus (http://www.t1dbase.org/page/Regions), is
not in LD with rs10272724 in IKZF1 (D’ =0 . 0 2 ,r
2 =0 . 0 0 0 1 ) ,
and we found by regression analysis that the two effects
were independent as both SNPs improve a model with the
other SNP included (P , 5.5 3 10
25).
The relative abundance of two different sets of IKZF1
transcripts in mRNA extracted from PBMCs isolated from
TABLE 1
Association of rs10272724 (T.C) near IKZF1 in 8,333 type 1 diabetes cases, 9,947 control subjects, and 3,997 families with type 1
diabetes
Sample set No. cases No. controls MAF cases MAF controls OR (95% CI) P*
Full case-control set 8,333 9,947 0.25 0.28 0.87 (0.83–0.91)† 4.8 3 10
29
Analysis of genotypes generated in the current report, within sample sets used by published GWA studies‡
Set 1 (T1DGC) 3,850 3,772 0.25 0.28 0.85 (0.79–0.91)† 1.6 3 10
25
Set 2 (WTCCC) 1,827 1,507 0.25 0.28 0.84 (0.76–0.92) 0.0014
Set 3 (Swafford) 2,666 4,668 0.26 0.28 0.90 (0.83–0.98) 0.011
No.
families
MAF
unaffected parents
No.
transmitted
No. not
transmitted
RR
(95% CI) P
Families with type 1 diabetes 3,997 0.27 1,423 1,642 0.87 (0.81–0.93) 7.6 3 10
25
Overall 1.1 3 10
211
MAF, minor allele frequency; RR, relative risk. *No evidence of deviation from a multiplicative allelic effects model was obtained (P = 0.33), so
P values assuming multiplicative allelic effects are reported. The overall P value was obtained by combining the P value from the case-control
sets and the family transmission disequilibrium test using Fisher’s method for combined probability. †This OR is subject to winner’s curse.
‡Barrett et al. (10) analyzed three datasets in their GWA study, two of which overlap with the samples in the current study. Barrett et al. used
the Illumina 550 K SNP chip to genotype rs10272724 in set 1 (4). Genotypes were 99.6% concordant between the Illumina platform and TaqMan
in the 3,850 cases and 3,772 controls genotyped using both technologies. Affymetrix 500 K Mapping Array genotypes for neighboring SNPs
were used to impute rs10272724 genotypes in set 2 by Barrett et al. because rs10272724 was not genotyped by Affymetrix. T1DGC, Type 1
Diabetes Genetics Consortium; WTCCC, Wellcome Trust Case-Control Consortium.
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determine the association of rs10272724 alleles with gene
expression. No evidence of allele-speciﬁc expression was
obtained (P . 0.1; Fig. 1). Others have reported a correla-
tion of rs4132601 with IKZF1 expression in Epstein–Barr
virus-transformed lymphoblastoid cell lines from the
HapMap GENEVAR resource ([8]; P=0.0017). However,
this is likely to be a false effect. The probe originally used
(Illumina ID ILMN_1676575) contains two high-frequency
SNPs in its target, rs62447207 (G.T) and rs62447208 (C.G)
in LD with rs10272724 (r
2 = 0.76), rendering it unreliable,
as evidenced by the absent IKZF1 probe in the latest
Genevar data from the study by Dimas et al. (14). In results
from 13 eQTL datasets displayed at http://eqtl.uchicago.edu/
cgi-bin/gbrowse/eqtl/, there is no reliable evidence for an
IKZF1-associated eQTL. Next, correlation of rs10272724
genotype and expression of nine transcripts from other
genes within 1 Mb of rs10272724 in three types of cell lines
was tested using the latest Genevar dataset by Dimas et al.
(14). No correlation was observed between rs10272724 and
expression of any of the ﬁve neighboring genes ([14],
Supplementary Fig. 1).
DISCUSSION
We provide evidence that the minor allele of rs10272724
(C), in near-perfect LD with the minor, C-ALL–susceptible,
allele of rs4132601 (G), is protective from type 1 diabetes.
Of the nearby genes in the region, IKZF1 appeared to be
the most likely candidate causal gene for type 1 diabetes in
this region given its causal role in C-ALL and its known
role in lymphocyte development. However, our analysis
revealed that the previously reported correlation of IKZF1
mRNA expression with rs4132601 may be inaccurate given
complications with the probe used in the data accessed by
Papaemmanuil et al. (8). Furthermore, an IKZF1 genotype-
phenotype correlation at rs10272724 was not conﬁrmed by
our qPCR analysis of PBMCs. IKZF1 is now an attractive
candidate causal gene in type 1 diabetes, and a functional
link between rs10272724 and IKZF1 may yet be elucidated
on examining speciﬁc isoforms of Ikaros. We note that our
qPCR assay evaluated the expression of two transcripts
conserved across 10 splice variants of IKZF1, spanning six
of the seven identiﬁed active and dominant-negative iso-
forms of the protein. In addition, many allele-speciﬁc effects
on gene expression are known to be tissue or cell-type
speciﬁc and may even be restricted to particular phases of
development. Another ALL-related gene, AF4/FMR2 family
member 3 (AFF3), has been associated with type 1 diabetes
(10) (J. Cooper, C.W., and J.A.T., unpublished observa-
tions), so our report also conﬁrms a second genetic link
between these diseases. AFF3 has been implicated as
a susceptibility allele in rheumatoid arthritis (rs10865035
and rs9653422) (16), further highlighting the connection
between autoimmunity and lymphoid cancers.
Our ﬁnding with IKZF1 marks the third Ikaros family
member to be associated with type 1 diabetes, the others
being the transcription factors Ailios (IKZF3)o nc h r o m o -
some 17q21.2 and Eos (IKZF4)o nc h r o m o s o m e1 2 q 1 3 . 2
(10,17), whose targets include BCL-2 and FOXP3,r e -
spectively. Ikaros family members interact to coordinate
functions of immunologic development and homeostasis
(18), so it will be important to explore the effect of these
interactions in disease etiology. The more than 30 reported
interaction partners of the Ikaros family members (http://
www.t1dbase.org) suggest the role of IKZF1 in type 1 di-
abetes could be subtle and yet far reaching. Interactions
with the histone deacetylase and chromodomain-helicase-
DNA-binding families of proteins suggest chromosome
remodeling events could be involved (11,19). Ikaros inter-
actions with the Notch (18) and STAT (20) protein families
also suggest that signaling events that affect T-cell activa-
tion and maturation could affect the ultimate development
of a diabetogenic, leukemia-protected or nondiabetogenic,
leukemia-susceptible T-cell repertoire. Thus, further inves-
tigation is warranted to elucidate the phenotypic effect of
the genetic feature marked by rs10272724, its impact on
IKZF1, and the role of Ikaros in autoimmunity.
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